INSIGHT 01Fact
91%
91% of applications are in Pharmaceuticals
337 applications in this field, 322 of them in IPC A61K — the main axis of the portfolio.
Method: Field applications ÷ applications with IPC
Company patentsOncology medicines and biopharmaceuticals
COMPANY PATENT INTELLIGENCE
Explore antibody and formulation technologies through reviewed current and historical names of BeOne Medicines and its Swiss subsidiary.
≥385docs
32 per month · peak 2025-03 (43)
Empty dashed outlines are uncollected periods, not zero. Dashed bars have partial name or date coverage.
INSIGHT 01Fact
91%
337 applications in this field, 322 of them in IPC A61K — the main axis of the portfolio.
Method: Field applications ÷ applications with IPC
372 applications with IPC codes are mapped to 35 fields using the WIPO IPC–Technology Concordance; area is the number of applications. Select a tile to see its IPC subclasses. An application can belong to several fields.
Publications per month in each field; brighter cells mean more. It shows which directions surge in particular months.
This chart covers collected documents published from 2025-01-01 to 2025-12-31. Examination and publication processes affect this timing; it does not directly measure R&D investment in the same period.
| Technology field | 25-01 | 25-02 | 25-03 | 25-04 | 25-05 | 25-06 | 25-07 | 25-08 | 25-09 | 25-10 | 25-11 | 25-12 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Pharmaceuticals | 25 | 35 | 38 | 28 | 34 | 29 | 19 | 32 | 21 | 25 | 39 | 20 |
| Organic fine chemistry | 14 | 19 | 17 | 19 | 21 | 15 | 10 | 19 | 12 | 17 | 27 | 16 |
| Biotechnology | 7 | 12 | 20 | 7 | 18 | 9 | 11 | 8 | 11 | 17 | 14 | 2 |
| Analysis of biological materials | 1 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Medical technology | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 |
| Chemical engineering | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 |
| Computer technology | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Documents in the current publication window are deduplicated by application number and grouped by filing year. These are not the company's complete annual filings; older applications may only be published or granted within this window.
Invention applications are generally published about 18 months after filing, or priority where claimed, and may be published earlier. Flags are estimated as of 2026-11-17. An unflagged year is still not necessarily complete; these counts cannot establish growth or contraction in R&D.
Multi-year evolution · With a longer collection window, this becomes a yearly view that marks the fastest-growing and shrinking fields.
Four reproducible structural ratios, with the other published companies on the same scale. Entity scopes and windows can differ, so read relative positions only — this is not a ranking.
Position 1 of 26 published companies.
Method: Sum of squared field shares
Position 9 of 26 published companies.
Method: Utility model documents ÷ all documents
The source has no CPC codes, so this cannot be computed.
Method: Documents with CPC Y02 ÷ documents with CPC
Position 24 of 26 published companies.
Method: Applications in measurement, chemical engineering, handling and machine tools ÷ all applications
Organisations that filed jointly with the collected entities; line weight represents joint applications. Name-based candidates and reviewed relationships are labeled separately. Co-applications alone do not prove ownership.
Possible affiliation is a review lead only. Co-applicants without a review record are not automatically group members or external partners, and their independent filings are not added to these statistics.
Review the entity listEntity review and data coverage are separate facts. This list shows the current entity configuration, evidence and relationship dates, matched name by name against this snapshot.
Filters change only the entity list below, not the statistics. A complete group snapshot is not available to switch to on this page.
Showing 2 of 2 entities
2025-05-27 母公司英文名称改为 BeOne Medicines Ltd.;合同明确 BeOne Medicines I GmbH 原名 BeiGene Switzerland GmbH。历史标准名按法人证据归并,不将全部 BeiGene/BeOne 前缀自动纳入。
Review evidence2025-05-27 母公司英文名称改为 BeOne Medicines Ltd.;合同明确 BeOne Medicines I GmbH 原名 BeiGene Switzerland GmbH。历史标准名按法人证据归并,不将全部 BeiGene/BeOne 前缀自动纳入。
Review evidenceRelationship dates help interpret renaming, acquisitions and joint ventures. Missing dates do not establish an indefinite relationship or verify the current patent owner.
Written by editors after reading the patent texts and company materials. Verified facts and inferences are labeled, each with evidence and limits.
Select a theme to filter reviewed patents and observations that cite them. Counts are editorial samples only; one patent may belong to several themes. They do not describe the full portfolio distribution.
Themes describe the technical directions in these samples. Links to adoption in specific products, commercialization or commercial value have not been established.
Showing 2 sample patents · 0 linked observations
Hand-picked documents that illustrate technology themes — not a ranking of core patents and not representative of the whole.
US20250034257A1
The abstract concerns viscosity and stability of anti-PD-1 formulations. Claim 1 combines approximately 10–200 mg/mL antibody, a buffer at about pH 5.0–7.0, a viscosity reducer and a non-ionic surfactant, with viscosity no greater than 35 cP and a specified osmolarity range. Although the title mentions arginine, this claim uses the broader term viscosity reducer.
US20250115671A1
The abstract presents antibodies and antigen-binding fragments that bind human CCR8. Claim 1 specifies three heavy-chain CDR alternatives paired with defined light-chain CDR sequences, differing in selected heavy-chain regions. It supports a reading of particular antibody structures, not a conclusion that a corresponding therapy is approved.
25 publication offices · 385 documents
Counts use the publication office of each collected document, retaining publications from the same family in different jurisdictions. This is not a map of complete families, granted or active rights; WO and EP denote international and European publication routes.
Invention grant
3-[(1h-pyrazol-4-yl)oxy]pyrazin-2-amine compounds as hpk1 inhibitor and use thereof
BEONE MEDICINES I GMBH
Organic fine chemistryPharmaceuticals
Other
Derivados de 5-amino-6,8-dihidro-1h-furo[3,4-d]pirrolo[3,2-b]piridin-2-carboxamida como inhibidores cooperativos con mta de prmt5
BEONE MEDICINES I GMBH
Organic fine chemistryPharmaceuticals
Invention publication
Heterocyclic compounds
BEONE MEDICINES I GMBH
Organic fine chemistryPharmaceuticals
Invention publication
Heterocyclic compounds, compositions thereof, and methods of treatment therewith
BEIGENE LTD
Organic fine chemistryPharmaceuticals
Invention publication
Bcl-xl inhibitors
BEIGENE LTD
Organic fine chemistryPharmaceuticals
Other
Compound as b-raf kinase dimer inhibitor and preparation method thereof
BEIGENE LTD
Organic fine chemistryPharmaceuticals
Invention publication
MUC1 Antibodies and Methods of Use
BEONE MEDICINES I GMBH
Biotechnology
Invention publication
Self-stabilizing linker conjugates
BEONE MEDICINES I GMBH
Organic fine chemistryPharmaceuticals
Other
Co-administration of mirdametinib and lifirafenib for use in treating cancers
BEIGENE LTD / SPRINGWORKS THERAPEUTICS INC
Pharmaceuticals
Other
A Medicament and Method of Treatment of Central Nervous System and/or Neuropsychiatric Disorders
BEIGENE SWITZERLAND GMBH / MASSEY VENTURES LTD
Pharmaceuticals
Invention publication
Heterocyclic compounds
BEONE MEDICINES I GMBH
Organic fine chemistryPharmaceuticals
Invention publication
Condensed heterocyclic compounds as inhibitor of diacylglycerol kinases
BEONE MEDICINES I GMBH
Organic fine chemistryPharmaceuticals
Invention publication
Condensed heterocyclic compounds as inhibitor of diacylglycerol kinases
BEONE MEDICINES I GMBH
Organic fine chemistryPharmaceuticals
Other
Conjugados de enlace autoestabilizantes
BEONE MEDICINES I GMBH
Organic fine chemistryPharmaceuticals
Other
Anticuerpos multiespecíficos anti–cd3 y métodos de uso
BEONE MEDICINES I GMBH
BiotechnologyPharmaceuticals
Other
Conjugados de enlace autoestabilizantes
BEONE MEDICINES I GMBH
Organic fine chemistryPharmaceuticals
Other
Targeted pyrrolobenzodiazapine conjugates
BEONE MEDICINES I GMBH
Organic fine chemistryPharmaceuticals
Other
Compounds for the degradation of egfr kinase
BEONE MEDICINES I GMBH
Organic fine chemistryPharmaceuticals
Invention publication
Solid forms comprising (s)-7-(1-acryloylpiperidin-4-yl)-2-(4-phenoxyphenyl)-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrimidine-3-carboxamide, and oxalic acid, compositions and methods of use thereof
BEIGENE SWITZERLAND GMBH
Organic fine chemistry
Invention publication
표적화된 피롤로벤조디아자핀 접합체
BEONE MEDICINES I GMBH
Organic fine chemistryPharmaceuticals
Titles come from the source bibliography. Select a number to read the full document on this site.
Upload your invention disclosure and get an editable draft that follows CNIPA practice.
Publications are deduplicated by publication number; applications by application number, so a publication and its grant count once; families by the source family ID. Technology fields are derived automatically from IPC codes using the WIPO IPC–Technology Concordance (March 2026), without manual or AI labeling.
Publication or grant documents do not establish current rights. Check legal status and current owners with the relevant patent office.
These statistics use only the applicant names and publication dates collected for this snapshot. They do not represent the full company or group portfolio.
The reviewed entities and aliases below describe the current company configuration. Only names listed above are covered by this snapshot.
BeOne Medicines I GmbH
Configured aliases: BeiGene Switzerland GmbH · BEIGENE SWITZERLAND GMBH · BEONE MEDICINES I GMBH
Original review note: 2025-05-27 母公司英文名称改为 BeOne Medicines Ltd.;合同明确 BeOne Medicines I GmbH 原名 BeiGene Switzerland GmbH。历史标准名按法人证据归并,不将全部 BeiGene/BeOne 前缀自动纳入。
Review evidenceBeOne Medicines Ltd.
Configured aliases: BeiGene, Ltd. · BEIGENE LTD · 百济神州有限公司
Original review note: 2025-05-27 母公司英文名称改为 BeOne Medicines Ltd.;合同明确 BeOne Medicines I GmbH 原名 BeiGene Switzerland GmbH。历史标准名按法人证据归并,不将全部 BeiGene/BeOne 前缀自动纳入。
Review evidenceFound a wrong attribution or number? Tell us